Dr Reddy's Laboratories, India's No. 2 drugmaker, will start to see the benefits from its tie-up with Britain's GlaxoSmithKline in two or three years, its chief executive said on Thursday. GV Prasad also reiterated that the company's founders had no plans to sell a stake in the business to GSK or another large drugmaker.
"Overall, it is a good relationship that is working well and going as predicted, but the financial impact is going to be seen only two to three years from now," he told Reuters on the sidelines of the World Economic Forum meeting.
"It takes time to develop the products and register them and launch them and wait for them to grow."
GSK signed a deal with Dr Reddy's in 2009 giving it access to the Indian firm's portfolio and its future pipeline of more than 100 branded generic pharmaceuticals. Dr Reddy's earlier this week reported a swing into profit in the third quarter.